Biological Context
Frataxin, a highly conserved protein found in prokaryotes and eukaryotes, is essential for cellular iron homeostasis (Babcock, 1997) . Protein deficiency in humans is the cause of the cardio-and neurodegenerative disorder Friedreich's ataxia (FRDA), which affects 1 in 50,000 (Delatycki, 2000) .
Although expressed ubiquitously in humans, tissues with high metabolic rates like those in cardiomuscle, nerve, kidney and liver are most affected by frataxin deficiency (Campuzano, 1996) . At a cellular level, the effects of frataxin deficiency include an increase mitochondrial iron levels and a decrease in activity of iron-sulfur (ISC)-containing proteins (Babcock, 1997; Rotig, 1997; Pandolfo, 2002) . Accumulating evidence suggests frataxin participates directly in Fe-S cluster bioassembly, either by serving as an iron chaperone that delivers Fe(II) to the cluster assembly enzyme IscU (Yoon, 2003; Kondapalli, 2008 ). An alternative hypothesis, with frataxin serving as a regulatory protein that controls assembly by interacting with partners within the pathway, has also been reported (Adinolfi, 2009 ). Frataxin's globular domain structure is conserved between prokaryotes and eukaryotes (see review (Bencze, 2006) ) suggesting a conserved function.
In eukaryotes, frataxin maturation occurs following a two-step proteolytic processing of the protein's N-terminus (Condo, 2007) . Processing of human frataxin's N-terminus involves cleaving residues 1-41 in the initial step and residues 42-80 in the final step (Condo, 2007; Schmucker, 2008) .
Additional extended variants of the "mature" (residues 81-210) human frataxin have also been found in vivo when maturation is impaired, including example constructs that span residues 56-210 and 78-210 (Schmucker, 2008) . The structure of human frataxin has been solved, both by NMR and X-ray crystallography, however complications from proteolysis and degradation of the protein's Nterminus hindered the characterization beyond residues 88-210 (Musco, 1999; Dhe-Paganon, 2000; Musco, 2000) . Preliminary biochemical data suggests the region N-terminal to residue 88 in human frataxin may be important in regulating the interaction between the protein and its partner IscU (Yoon, 2007) . A section of the N-terminal region in mature yeast frataxin is structured, suggesting this region that is extended beyond the globular domain of the protein may play a functional role (He, 2004) . In order to provide a structural basis for understanding the significance of the Nterminal region in full-length human frataxin, and the N-terminal extension section in processing variants, towards iron and protein partner binding, we characterized a stable extended full-length human frataxin construct spanning residues 45-210 by NMR spectroscopy and obtained nearly complete resonance assignments of these residues. These assignments set the basis for solving the complete solution structure of full-length human frataxin and for mapping intermolecular interactions between full-length human frataxin and binding partners. Preliminary data suggest a high structural similarity between our 45-210 construct and the truncated forms of the proteins that have been solved previously by NMR (Musco, 2000) . Dispersion of amide resonances in the 15 N HSQC spectra of labeled human frataxin (Figure 1) indicates the protein is well folded. Overlays of 15 N HSQC spectra for truncated human frataxin (residues 91-210) (Musco, 1999) (Wishart, 1991) suggests that while a subset of residues in this region 
Methods and Experiments
Labeling, Expression and Purification of Human Frataxin -15 N-labeled and 13 C/ 15 N doubly labeled human frataxin spanning amino acids 45 to 210 were obtained from bacteria grown in M9 minimal medium with 15 NH4Cl and U-13 C6 D-glucose as the sole nitrogen and carbon sources respectively.
The construct contained an N-terminal poly-His tag which was included for purification purposes and not removed (Yoon, 2007) . The constructs were expressed in E. coli BL21 (DE3) strain transformed with a modified pET 28b(+) vector DNA. For protein expression, the cells were inoculated into 4 liters of M9 medium with kanamycin (50 mg/L) induced for 16 hours by addition of 0.3 mM IPTG after the cultures reached an optical density between 0.4 -0.6 at 600 nm.
Cell pellets were resuspended in buffer A (50 mM sodium phosphate, 300 mM NaCl, 10% glycerol, pH 7.0) supplemented with 1 mM TCEP, 0.1% Triton X-100, 75 ng/mL lysozyme, DNase I. Cell lysis was achieved by sonication (10 s pulse / 2 min) for 30 min at 4°C. Lysate was centrifuged at 15,000 rpm for 30 min at 4°C. The supernatant was loaded onto a TALON resin preequilibrated with buffer A. Subsequently, the loaded resin was washed with 10 bed volumes of buffer A, 5 bed volumes of buffer A with 5 mM imidazole and 5 bed volumes of buffer A with 10 mM imidazole. Protein was eluted with buffer A and 200 mM imidazole, pH 7.0. Protein purity was assessed by SDS-PAGE.
For NMR experiments, buffer was exchanged by dialysis against 100 mM sodium phosphate, pH 7.5.
Concentration was determined by absorbance at 280 nm (ε280 = 33920 M -1 cm -1 ).
Nuclear Magnetic Resonance Spectroscopy (NMR) -Frataxin samples used in the structure determination were prepared at 1 mM concentration in NMR buffer (100 mM sodium phosphate, pH 7.5, 90% H2O and 10% D2O). NMR spectra were acquired at 300 K on an Varian INOVA 600 MHz spectrometer equipped with a triple resonance 1 H/ 13 C/ 15 N Varian cold probe with z-axis pulsed field gradients. Sequence specific backbone assignments were done using the following experiments: 15 N-HSQC, HNCACB, CBCA(CO)NH and HNCO (Cavanagh 1996) . Side chain atom assignments were made using 1 H-13 CHSQC, H(CCO)NH-TOCSY, C(CO)NHTOCSY and 15 N-filtered TOCSY experiments. All spectra were analyzed according to established lab protocols (He, Alam et al. 2004) NMR assignments of a stable processing intermediate of human frataxin| K. Kondapalli, et. al DIGITALCOMMONS@WSU | 2010 6 using the processing programs NMRPipe (Delaglio, Grzesiek et al. 1995) and Sparky (Goddard and Kneller 2001) .
Assignments and Data Deposition
Residue assignments for the full-length human frataxin protein are provided in the high-resolution 15 N-HSQC spectrum for the protein (Figure 1) . Full backbone and side chain assignments was achieved for 160 out of 167 possible residues. For further reference, the residue sequence for fulllength human frataxin can be found at http://www.uniprot.org/uniprot/Q16595. Chemical shift assignments are deposited in the Biological Magnetic Resonance Bank (http://www.bmrb.wisc.edu/) under the accession code BMRB-15736.
